0000950170-24-071532.txt : 20240610
0000950170-24-071532.hdr.sgml : 20240610
20240610193844
ACCESSION NUMBER: 0000950170-24-071532
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240610
FILED AS OF DATE: 20240610
DATE AS OF CHANGE: 20240610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HEALY JAMES
CENTRAL INDEX KEY: 0001245624
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-42121
FILM NUMBER: 241034326
MAIL ADDRESS:
STREET 1: 3000 SAND HILL ROAD, 4-250
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Rapport Therapeutics, Inc.
CENTRAL INDEX KEY: 0002012593
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 880724208
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1325 BOYLSTON STREET
STREET 2: SUITE 401
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: 857-321-8020
MAIL ADDRESS:
STREET 1: 1325 BOYLSTON STREET
STREET 2: SUITE 401
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
ownership.xml
4
X0508
4
2024-06-10
0002012593
Rapport Therapeutics, Inc.
RAPP
0001245624
HEALY JAMES
RAPPORT THERAPEUTICS, INC.
1325 BOYLSTON STREET, SUITE 401
BOSTON
MA
02215
true
false
false
false
false
Common Stock
2024-06-10
4
C
false
1392738
0.00
A
1392738
I
By Sofinnova Venture Partners XI, L.P.
Common Stock
2024-06-10
4
P
false
470589
17.00
A
1863327
I
By Sofinnova Venture Partners XI, L.P.
Common Stock
2024-06-10
4
P
false
18641
17.00
A
18641
I
By Sofinnova Synergy Master Fund LP
Common Stock
2024-06-10
4
P
false
17861
17.00
A
17861
I
By Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP
Common Stock
2024-06-10
4
P
false
26278
17.00
A
26278
I
By Crestline Summit Master, SPC - PEAK SP
Common Stock
2024-06-10
4
P
false
25455
17.00
A
25455
I
By CRESTLINE SUMMIT PINNACLE MASTER, L.P.
Series B Preferred Stock
2024-06-10
4
C
false
11924138
0.00
D
Common Stock
1392738
0
I
By Sofinnova Venture Partners XI, L.P.
Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Series B Preferred Stock had no expiration date.
The shares are directly held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. ("SM XI") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
The shares are directly held by Sofinnova Synergy Master Fund LP ("Synergy Fund"). Sofinnova Synergy GP, LLC ("Synergy Fund GP") is the general partner of Synergy Fund. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by Synergy Fund. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
The shares are directly held by Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP ("APEX SP"). Synergy Fund GP is the general partner of APEX SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by APEX SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
The shares are directly held by Crestline Summit Master, SPC - PEAK SP ("PEAK SP"). Synergy Fund GP is the general partner of PEAK SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by PEAK SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
The shares are directly held by CRESTLINE SUMMIT PINNACLE MASTER, L.P. ("Pinnacle LP"). Synergy Fund GP is the general partner of Pinnacle LP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by Pinnacle LP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
/s/ Cheryl Gault, Attorney-in-Fact
2024-06-10